75985-18-1

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 5-(AMINOMETHYL)THIOPHENE-2-CARBOXYLATE is used as a precursor for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and properties make it a valuable building block in the development of new drugs and bioactive compounds.
Used in Medicinal Chemistry:
METHYL 5-(AMINOMETHYL)THIOPHENE-2-CARBOXYLATE is used as a precursor in medicinal chemistry for the preparation of bioactive compounds. Its ability to serve as a building block in organic synthesis makes it a promising candidate for the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
METHYL 5-(AMINOMETHYL)THIOPHENE-2-CARBOXYLATE is used as a valuable building block in organic synthesis. Its unique structure and properties make it useful for the synthesis of a wide range of compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals.

Upstream product

• 503470-01-7 5-azidomethylthiophene-2-carboxylic acid methyl ester 
• 1918-79-2 2-methylthiophene-5-carboxylic acid 
• 19432-69-0 methyl 5-methylthiophene-2-carboxylate 
• 108499-32-7 5-bromomethyl-2-carbomethoxythiophene 

Downstream Products

• 476362-82-0 5-[(3-carboxy-4-hydroxy-benzenesulfonylamino)-methyl]-thiophene-2-carboxylic acid methyl ester 
• 830331-51-6 5-[(4-chloro-benzoylamino)-methyl]-thiophene-2-carboxylic acid methyl ester 
• 830331-52-7 5-[(4-chloro-benzoylamino)-methyl]-thiophene-2-carboxylic acid 
• 476362-84-2 5-[(3-tert-butoxycarbonyl-4-hydroxy-benzenesulfonylamino)methyl]thiophene-2-carboxylic acid 
• 476362-83-1 5-[(3-tert-butoxycarbonyl-4-hydroxy-benzenesulfonylamino)methyl]thiophene-2-carboxylic acid methyl ester 
• 503470-03-9 5-[(5-{1-tert-butoxycarbonylmethyl-2-[5-(2,6-dichloro-phenyl)-oxazol-2-yl]-2-oxo-ethylcarbamoyl}-thiophen-2-ylmethyl)-sulfamoyl]-2-hydroxy-benzoic acid tert-butyl ester 
• 503470-02-8 5-[(5-{1-tert-butoxycarbonylmethyl-2-[5-(2,6-dichloro-phenyl)-oxazol-2-yl]-2-hydroxy-ethylcarbamoyl}-thiophen-2-ylmethyl)-sulfamoyl]-2-hydroxy-benzoic acid tert-butyl ester 
• 1218923-51-3 C₁₄H₁₃NO₄S 

Relevant academic research and scientific papers

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

Synthesis and antiplasmodial activity of new heteroaryl derivatives of 7-chloro-4-aminoquinoline

With the aim to investigate the effect of different heterocyclic rings linked to the 4-aminoquinoline nucleus on the antimalarial activity, a set of 7-chloro-N-(heteroaryl)-methyl-4-aminoquinoline and 7-chloro-N-(heteroaryl)-4- aminoquinoline was synthesi

Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase

Several lines of evidence support the hypothesis that c-Jun N-terminal kinases (JNKs) play a critical role in a wide range of disease states including cell death (apoptosis)-related and inflammatory disorders (epilepsy, brain, heart and renal ischemia, ne

Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design

The design, synthesis, and in vitro activities of a series of potent and selective small-molecule inhibitors of caspase-3 are described. From extended tethering, a salicylic acid fragment was identified as having binding affinity for the S4 pocket of caspase-3. X-ray crystallography and molecular modeling of the initial tethering hit resulted in the synthesis of 4, which reversibly inhibited caspase-3 with a Ki = 40 nM. Further optimization led to the identification of a series of potent and selective inhibitors with Ki values in the 20-50 nM range. One of the most potent compounds in this series, 66b, inhibited caspase-3 with a Ki = 20 nM and selectivity of 8-500-fold for caspase-3 vs a panel of seven caspases (1, 2, and 4-8). A high-resolution X-ray cocrystal structure of 4 and 66b supports the predicted binding modes of our compounds with caspase-3.

N-Substituted aziridine-2-carboxylic acid derivatives for immuno stimulation

Aziridine-2-carboxylic acid derivatives of the formula STR1 wherein X is a carboxyl, nitrile, alkoxycarbonyl or carbamoyl group, and R and R1 are various organic radicals, or pharmacologically acceptable salts thereof, exhibit marked immunostimulant activity, especially in conjunction with added chemotherapeutic agents such as a penicillin, a cephalosporin, a nitrofuran or chloramphenicol. Those compounds are new where X is a cyano group or an alkoxycarbonyl radical and R1 is a hydrogen atom, but R' is not an unsubstituted alkyl radical or an alkyl radical substituted by hydroxyl, alkoxy, dialkylamino, phenyl, 4-chlorophenyl or 4-methoxyphenyl or a vinyl radical substituted by a phenyl or methyl radical, or a cycloalkyl radical, a phenyl a 4-chlorophenyl, a 4-methoxyphenyl, an s-triazinyl or a pyridinyl radical; or where X is a carbamoyl group and R1 is a hydrogen atom, R' is not an unsubstituted cyclohexyl, alkyl or benzyl radical; or where X is a cyano group or an alkoxycarbonyl radical and R1 is a phenyl radical, R' is not an isopropyl, cyclohexyl, phenyl, benzyl or p-chlorobenzyl radical; or where R1 is a methyl radical, R1 is not a benzyl, p-chloro- or p- methoxybenzyl radical.